Neurontin Purchasers Ask To Amend Class Definition

Law360, New York (April 29, 2010, 5:57 PM EDT) -- Direct purchaser plaintiffs seeking class certification in multidistrict litigation accusing Pfizer Inc. of using patent litigation to delay generic competition for epilepsy drug Neurontin have requested to supplement their certification request by adding generic unit buyers to their proposed class definition.

Louisiana Wholesale Drug Co. Inc., Meijer Inc. and Meijer’s distribution unit argued in a motion filed Wednesday in the U.S. District Court for the District of New Jersey that, if the court rejects the precedent that the “generic bypass” is legally irrelevant with respect to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.